BioCentury
ARTICLE | Politics & Policy

Avalere: Patients could pay more for Part D biosimilars

April 13, 2016 12:22 AM UTC

An Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN) and Humira adalimumab from AbbVie Inc. (NYSE:ABBV), would have biosimilar competitors by next year. ...